针对PD-L1的新型分子设计:免疫调节技术的最新进展和癌症治疗的新见解
Feng Zhang1, Ruyue Ni1, Liang Qian1
1Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing 313299, China; Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing 313299, China.
针对编程死亡配体1 (PD-L1) 的新型策略正在推进癌症免疫疗法. 双功能抑制剂和蛋白质降解技术提供了更好的疗效,并克服抗性,以获得更好的抗瘤免疫力.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 编程死亡配体1 (PD-L1) 是瘤免疫逃避的关键调解者.
- 目前的抗PD-L1疗法存在局限性,包括低于最佳的疗效和耐药性.
- 准PD-L1对于增强癌症免疫疗法至关重要.
研究的目的:
- 审查PD-L1向分子用于癌症免疫治疗的最新进展.
- 探索破坏瘤免疫逃逸的新型作用机制.
- 讨论下一代PD-L1调制策略的治疗潜力.
主要方法:
- 对针对PD-L1和其他途径的新兴双功能小分子抑制剂的审查.
- 分析蛋白质降解策略,如针对PD-L1消除的PROTACs.
- 探索生物对等化学和酶体向药物输送方面的创新.
主要成果:
- 双功能抑制剂可以增强瘤的透力,克服瘤的抵抗力.
- 蛋白质降解技术通过蛋白质体或 lysosomal 途径提供持久的治疗效果.
- 新技术承诺更精确的药物输送和减少全身毒性.
结论:
- 新的PD-L1向策略正在彻底改变癌症治疗.
- 这些方法破坏了瘤的免疫逃逸,并增强了抗瘤免疫力.
- 创新为下一代癌症免疫疗法铺平了道路,改善了结果.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
09:06Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
Published on: February 3, 2023
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
